ロード中...
Stevens-Johnson Syndrome Induced by Vandetanib
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival....
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3276793/ https://ncbi.nlm.nih.gov/pubmed/22346274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5021/ad.2011.23.S3.S343 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|